Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630019 · ClinicalTrials.gov registry record · Phase 4
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
A Phase 4 study of Cataract, sponsored by Santen.
- Completed
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00630019: Completed Phase 4 study of Cataract, sponsored by Santen.
NCT00630019 is a Phase 4 study of Cataract that has completed, run by Santen. The registered enrollment target is 96 participants, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00630019, a Phase 4 study of Cataract, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.
Conditions Studied
Interventions
- DRUG 1.5% levofloxacin ophthalmic solution
- DRUG 0.5% moxifloxacin hydrochloride ophthalmic solution
Study Locations (1)
Pennsylvania
- Bucci Laser Vision & Ambulatory Surgery Center - Wilkes-Barre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2008-02 |
| Phase | Phase 4 |
What the finished NCT00630019 record still lists
NCT00630019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which 1.5% levofloxacin ophthalmic solution is the first listed.
NCT00630019 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00630019 about?
NCT00630019 is a clinical study titled "Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator". Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.
What is the current status of trial NCT00630019?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2008-02.
What conditions does trial NCT00630019 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00630019?
The interventions under investigation include: 1.5% levofloxacin ophthalmic solution (DRUG), 0.5% moxifloxacin hydrochloride ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00630019?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630019 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00630019's enrollment target sits among peer trials
96 39th of 83 higher than 44 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia